<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726309</url>
  </required_header>
  <id_info>
    <org_study_id>ICORG 08-40</org_study_id>
    <nct_id>NCT01726309</nct_id>
  </id_info>
  <brief_title>Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4</brief_title>
  <official_title>Correlation of Single Nucleotide Polymorphism (SNP) Profile of Domain III of EGFR to Skin and/or Eye Toxicity and Disease Response to Treatment With Cetuximab or Panitumumab - SNP and Cetuximab or Panitumumab Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and
      the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.

      Secondary Objectives:

      Correlation of SNP profile with indicators of tumour response parameters, such as
      radiological response, duration of response, time to progression (TTP), overall survival (OS)
      time, incidence of non-dermatological adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline assessment:

        -  Contact Lenses

        -  Medical History

        -  Previous chemotherapy

        -  Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)

        -  Symptom Assessment (Pre-existing skin and/or eye conditions, CEA measurement (CRC only),
           Disease status (TNM Staging))

        -  Planned chemotherapy regimen

        -  Radiotherapy

      Blood Sample: A 2ml blood sample should be collected in ethylenediamine-tetraacetic acid
      (EDTA) containing Vacutainer at any time before or after starting treatment. DNA will be
      extracted from the samples and the 11 SNPs in the region of the EGFR gene encoding domain III
      will be characterized.

      Follow-up Assessment: with every second cycle of Cetuximab- or Panitumumab-containing regimen
      (CRC: every 2. Week; NSCLC: every 3-4 weeks):

        -  Visit Number and Date

        -  Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)

        -  Symptom Assessment (CEA measurement (CRC only), Disease status (TMN Staging), Skin
           Toxicity (CTCAE) grading)

        -  Current chemotherapy regimen

        -  Radiotherapy

        -  CEA measurement only for CRC (every second cycle/every 4 weeks)

      Long-term follow-up (up to 5 years):

        -  CT restaging (TNM Staging) should be done 3 monthly for as long as the subject is
           receiving Cetuximab- or Panitumumab- containing regimen or if there is suspicion of
           disease progression.

        -  OS
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region.</measure>
    <time_frame>Throughout treatment with up to 5 years in follow up</time_frame>
    <description>Using Common Terminology Criteria for Adverse Events (CTCAE) version 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between the SNP profile(s) and disease response</measure>
    <time_frame>Throughout treatment with up to 5 years in follow up</time_frame>
    <description>Time to progression TTP and OS over 5 years</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Stage IV CRC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage IV NSCLC</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient Population:

        150 Patients with histologically proven stage IV (AJCC 7th Edition) colorectal cancer (CRC)
        expressing wild-type KRAS or stage IV non-small cell lung cancer (NSCLC) expressing EGFR
        (tested by immunohistochemistry (IHC)), with no previous exposure to Cetuximab or
        Panitumumab, who will receive treatment with an EGFR-antibody (Cetuximab or Panitumumab).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stage IV (AJCC 7th Edition TMN Staging, Appendix C), histologically confirmed CRC with
             wild-type KRAS and not a candidate for metastasectomy.

          2. Stage IV (AJCC 7th Edition, TMN Staging, Appendix C) NSCLC expressing EGFR (IHC
             tested)

          3. Patients, who will receive treatment with an EGFR-antibody (Cetuximab or Panitumumab).

          4. Karnofsky performance status (Appendix B) score ≥60.

          5. Acceptable laboratory values:

               -  Haemoglobin ≥ 9 g/dL.

               -  Neutrophil count ≥ 1.0 x 10^9/L.

               -  Platelet count ≥100 x 10^9/L.

               -  Serum creatinine ≤1.5 times the upper limit of normal.

               -  Bilirubin ≤1.5 times the upper limit of normal.

               -  Aspartate aminotransferase and alanine aminotransferase ≤5 times the upper limit
                  of normal.

        Exclusion Criteria:

          1. Aged &lt; 18 years

          2. Prior exposure to Cetuximab or Panitumumab

          3. The CRC does not carry wild-type KRAS.

          4. The NSCLC stains negative for EGFR protein expression

          5. Second cancer diagnosis (apart from non-melanoma skin cancer)

          6. Known hypersensitivity to Cetuximab or Panitumumab, or murine protein.

          7. Known history of coronary artery disease, arrhythmias, or congestive heart failure (If
             the treating physician feels that a patient's coronary artery disease / arrhythmia /
             congestive heart failure does not place him/her at risk from treatment with an
             anti-EGFR antibody, the person can be included. This is a clinical decision, which has
             to be made by the treating physician).

          8. Known to be pregnant (pregnancy test is not mandatory) or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Letterkenny General Hospital</name>
      <address>
        <city>Letterkenny</city>
        <state>Donegal</state>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>074-9123798</phone>
    </contact>
    <investigator>
      <last_name>Karen Duffy, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact person</last_name>
      <phone>021-4542807</phone>
    </contact>
    <investigator>
      <last_name>Brian Bird, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact person</last_name>
      <phone>021-4546400</phone>
    </contact>
    <investigator>
      <last_name>Seamus O'Reilly, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-4142012</phone>
    </contact>
    <investigator>
      <last_name>Ray McDermott, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-8545075</phone>
    </contact>
    <investigator>
      <last_name>David Gallagher, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-8093000</phone>
    </contact>
    <investigator>
      <last_name>Liam Grogan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Adelaide &amp; Meath Hosptal, Dublin Incorporating The National Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>(01) 414 2000</phone>
    </contact>
    <investigator>
      <last_name>Ray McDermott, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact person</last_name>
      <phone>091-524222</phone>
    </contact>
    <investigator>
      <last_name>Gregory Leonard, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Hospital, Drogheda</name>
      <address>
        <city>Louth</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>(041) 9837601</phone>
    </contact>
    <investigator>
      <last_name>Bryan Hennessy, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterford Regional Hospital</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>051-848000</phone>
    </contact>
    <investigator>
      <last_name>Anne Horgan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2012</study_first_submitted>
  <study_first_submitted_qc>November 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2012</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

